Paul C. Grint, M.D.
Paul Grint is the President of Cerexa. Dr. Grint has significant experience in anti-infective,
oncology, and inflammation research and clinical development in both domestic and
international markets. Prior to joining Cerexa, Dr. Grint was a Senior Vice President
at Forest Research Institute, Inc., a subsidiary of Forest Laboratories, Inc. Prior
to joining Forest Laboratories, Dr. Grint was the Chief Medical Officer at Kalypsys
Inc., a biopharmaceutical company based in San Diego, California. Before joining
Kalypsys, Dr. Grint served as a Senior Vice President and Chief Medical Officer
of Zephyr Sciences, and has previously held similar positions at Pfizer La Jolla,
IDEC Pharmaceuticals, and Schering-Plough Research Institute (SPRI). Dr. Grint received
his Bachelor’s degree from St. Mary’s Hospital, London, and his medical degree at
University of London, St. Bartholomew's Hospital Medical College, and is a Fellow
of the Royal College of Pathologists.
Ian A. Critchley, Ph.D.
Ian Critchley is the Vice President of Clinical Microbiology at Cerexa. Dr. Critchley
joined Cerexa in June 2008, bringing more than 20 years of experience in antibacterial
drug discovery and development. Prior to joining Cerexa, Dr. Critchley was Executive
Director of Microbiology at Replidyne, where he led a team responsible for all pre-clinical
and clinical microbiology studies on antibacterial agents in the development pipeline.
Dr. Critchley came to Replidyne from Focus Technologies (now Eurofins Medinet) where
he was Director of Laboratory Services. There he established a microbiology laboratory
that provides contract research services to evaluate new agents in IND- and NDA-enabling
studies and monitors resistance in global surveillance studies. Prior to joining
Focus Technologies, Dr. Critchley was a Senior Investigator and Group Leader in
Microbiology Research at SmithKline Beecham Pharmaceuticals where he led discovery
research groups in both the U.K. and Philadelphia. Dr. Critchley holds a Ph.D. in
Microbiology from the University of Glasgow, Scotland, U.K. and a B.Sc. (Hons) in
Microbiology from University College, Cardiff, Wales, U.K. Dr. Critchley is a member
of the American Society for Microbiology, the U.K. Society for General Microbiology
and the British Society for Antimicrobial Chemotherapy.
David Friedland, M.D., M.B.A.
David Friedland is the Vice President of Clinical Sciences at Cerexa. Dr. Friedland
joined Cerexa in June 2008 and has extensive experience in the study of infectious
diseases, encompassing both academia and the pharmaceutical industry. Prior to joining
Cerexa, Dr. Friedland was Senior Director of Clinical Research at Theravance from
2005, where he was responsible for the hospital-acquired pneumonia program and a
major contributor to the NDA for telavancin, a gram-positive antibacterial agent.
Dr. Friedland came to Theravance from Migenix, a biopharmaceutical company in Vancouver,
BC, where he developed antibacterial and antiviral agents. Dr. Friedland served
in various positions over an eight year period, most recently as Vice President,
Clinical and Medical Affairs. Dr. Friedland obtained his M.D. and Master of Medicine
(Microbiology) degree from the University of the Witwatersrand, Johannesburg, South
Africa. He also holds an M.B.A. from Queens University, ON, Canada and is a Fellow
of the Infectious Diseases Society of America.
Jon Lee, Vice President of Clinical Operations, joined Cerexa in June 2006. Mr.
Lee served in positions of increasing responsibility at Nektar Therapeutics/Inhale
Therapeutic Systems, Inc. from 1999 until joining Cerexa. Prior to Nektar, he held
various positions within Clinical Operations at Gilead Sciences and Genentech, Inc.
Mr. Lee has developed and managed departments and interdisciplinary project teams
in each discipline of drug development in therapeutic areas including infectious
disease, oncology, neurology, and pulmonology. Mr. Lee graduated from the University
of Illinois with a B.S. in Chemistry.
Trisha Dobson, M.B.A., P.M.P.
Trisha Dobson is the Executive Director of Project Management at Cerexa. Ms. Dobson
was part of the team that founded Cerexa and currently heads the Project Management
function. Ms. Dobson has worked in many stages of development throughout her career
and leads the product team for a key antibiotic product. Prior to Cerexa, Ms. Dobson
held positions in Project Management at Peninsula Pharmaceuticals. Before working
at Peninsula Pharmaceuticals, Ms. Dobson developed and directed the Project Management
department at Cerus, instituting a number of key business and strategic management
tools. She has been in the industry for more than 15 years, working in both the
pharmaceutical and diagnostic environments, and has held key roles on a number of
international projects. Ms. Dobson received a B.S. from Case Western University
and holds an M.B.A. from St. Mary’s University. Ms. Dobson is a certified P.M.P.
(Project Management Professional).
Kristina Haeckl, RAC
Kristina Haeckl is the Executive Director, Regulatory Affairs at Cerexa. Ms. Haeckl
has extensive experience in the development and implementation of new drugs and products
in the biotech and pharmaceutical industry. Her experience includes interactions with
both domestic and international regulatory agencies and she has been involved with
complex industry strategic partnerships. Ms. Haeckl has held positions of increasing
responsibility over the last twenty years. Most recently, Ms. Haeckl was the Senior
Director, Regulatory Affairs and Quality Systems at MAP Pharmaceuticals. Prior to MAP,
she was the Director of Regulatory Sciences at Replidyne. Ms. Haeckl has also held
regulatory positions at Allos Therapeutics, Inc., OSI Pharmaceuticals (formerly Gilead
and NeXstar), Cortech, Inc., and Syntex USA. She was the founder of Kristina Haeckl and
Associates and served as Principal Consultant. Ms. Haeckl holds a BA in Environmental,
Population, and Organismic Biology from the University of Colorado at Boulder and has
achieved Regulatory Affairs Certification (RAC) through the Regulatory Affairs